Yumi Mendez-Ishizaki
Obstetrics & Gynecology · Long Beach, CANPI 1942723994
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,102 and has fallen 74.3% since, to $283 in 2022.
Across 100 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$362
- Myovant Sciences Inc.$241
- Pfizer$161
- GSK$160
- Amgen$99
- Johnson & Johnson$86
- plus $812 from 23 others
What the payments were for
- Food & beverage$1,90499%
- Education$171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 20 | $362 |
| Myovant Sciences Inc. | 11 | $241 |
| Pfizer | 9 | $161 |
| GSK | 8 | $160 |
| Amgen | 4 | $99 |
| Johnson & Johnson | 4 | $86 |
| Therapeuticsmd, Inc. | 4 | $74 |
| Novo Nordisk | 4 | $68 |
| Merck | 3 | $67 |
| Nestle Healthcare Nutrition Inc. | 3 | $63 |
| Exeltis, USA Inc. | 3 | $57 |
| Mayne Pharma Commercial LLC | 3 | $55 |
| Bayer | 3 | $55 |
| Organon | 2 | $45 |
| Boehringer Ingelheim | 2 | $39 |
| Lilly USA, LLC | 2 | $36 |
| AstraZeneca | 2 | $35 |
| Evofem Biosciences, Inc. | 2 | $31 |
| Covidien LP | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Olympus America Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Grifols USA, LLC | 1 | $17 |
| Phadia US Inc. | 1 | $14 |
| Mylan Pharmaceuticals Inc. | 1 | $13 |
| Biomerieux Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYFEMBREE$123
How this compares
$1,921 in reported general payments places this provider in the 75th percentile of 3,784 obstetrics & gynecology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 18 | $716 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Long Beach
- Steve YuNorthridge$964K
- Samir HageRedlands$640K
- Malcolm MunroLos Angeles$609K
- Michael KrychmanCosta Mesa$547K
- Anita NelsonTorrance$530K
- Jan SegnitzSan Jose$511K
- Risa KaganBerkeley$497K
- Michael GreenOxnard$424K
- Howard SalvaySanta Cruz$421K
- Marc WinterLaguna Hills$399K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.